Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry.

Hypersensitivity pneumonitis idiopathic pulmonary fibrosis interstitial lung disease survival

Journal

Lung India : official organ of Indian Chest Society
ISSN: 0970-2113
Titre abrégé: Lung India
Pays: India
ID NLM: 8405380

Informations de publication

Date de publication:
Historique:
entrez: 6 1 2021
pubmed: 7 1 2021
medline: 7 1 2021
Statut: ppublish

Résumé

Predictors of survival for interstitial lung disease (ILD) in the Indian population have not been studied. The primary objective of the study was to assess the Modified-Gender Age and Physiology (M-GAP) score to predict survival in patients with ILD seen in clinical practice. We also analyzed the role of demographic and radiological characteristics in predicting the survival of patients with ILD. In the ILD India registry, data were collected from 27 centers across 19 cities in India between March 2012 and June 2015. A single follow-up was conducted at 18 centers who agreed to participate in the follow-up in 2017. M-GAP score (range 0-5) was calculated with the following variables: age (≤60 years 0, 61-65 years 1, and >65 years 2), gender (female 0, male 1), and forced vital capacity% (>75% 0, 50%-75% 1, and >75% 2). A score of 0-3 and score of 4 and 5 were classified into Stage 1 and 2, respectively. Other predictors of survival, such as the history of tuberculosis, smoking, and the presence of honeycombing on computed tomography scan, were also evaluated. Nine hundred and seven patients were contacted in 2017. Among them, 309 patients were lost to follow-up; 399 were alive and 199 had died. M-GAP was significantly associated with survival. Similarly, other predictors of survival were ability to perform spirometry (hazard ratio [HR]: 0.49, 95% confidence interval [CI]: 0.34-0.72), past history of tuberculosis (HR: 1.57, 95% CI: 1.07-2.29), current or past history of smoking (HR: 1.51, 95% CI: 1.06-2.16), honeycombing (HR: 1.81, 95% CI: 1.29-2.55), a diagnosis of connective tissue disease -ILD (HR: 0.41, 95% CI: 0.22-0.76), and sarcoidosis (HR: 0.24, 95% CI: 0.08-0.77). In a subgroup of patients with newly diagnosed ILD enrolled in ILD India registry and who were available for follow-up, M-GAP score predicted survival. Honeycombing at the time of diagnosis, along with accurate history of smoking, and previous history of tuberculosis were useful indices for predicting survival.

Sections du résumé

BACKGROUND BACKGROUND
Predictors of survival for interstitial lung disease (ILD) in the Indian population have not been studied. The primary objective of the study was to assess the Modified-Gender Age and Physiology (M-GAP) score to predict survival in patients with ILD seen in clinical practice. We also analyzed the role of demographic and radiological characteristics in predicting the survival of patients with ILD.
MATERIALS AND METHODS METHODS
In the ILD India registry, data were collected from 27 centers across 19 cities in India between March 2012 and June 2015. A single follow-up was conducted at 18 centers who agreed to participate in the follow-up in 2017. M-GAP score (range 0-5) was calculated with the following variables: age (≤60 years 0, 61-65 years 1, and >65 years 2), gender (female 0, male 1), and forced vital capacity% (>75% 0, 50%-75% 1, and >75% 2). A score of 0-3 and score of 4 and 5 were classified into Stage 1 and 2, respectively. Other predictors of survival, such as the history of tuberculosis, smoking, and the presence of honeycombing on computed tomography scan, were also evaluated.
RESULTS RESULTS
Nine hundred and seven patients were contacted in 2017. Among them, 309 patients were lost to follow-up; 399 were alive and 199 had died. M-GAP was significantly associated with survival. Similarly, other predictors of survival were ability to perform spirometry (hazard ratio [HR]: 0.49, 95% confidence interval [CI]: 0.34-0.72), past history of tuberculosis (HR: 1.57, 95% CI: 1.07-2.29), current or past history of smoking (HR: 1.51, 95% CI: 1.06-2.16), honeycombing (HR: 1.81, 95% CI: 1.29-2.55), a diagnosis of connective tissue disease -ILD (HR: 0.41, 95% CI: 0.22-0.76), and sarcoidosis (HR: 0.24, 95% CI: 0.08-0.77).
CONCLUSION CONCLUSIONS
In a subgroup of patients with newly diagnosed ILD enrolled in ILD India registry and who were available for follow-up, M-GAP score predicted survival. Honeycombing at the time of diagnosis, along with accurate history of smoking, and previous history of tuberculosis were useful indices for predicting survival.

Identifiants

pubmed: 33402631
pii: LungIndia_2021_38_1_5_306014
doi: 10.4103/lungindia.lungindia_414_20
pmc: PMC8066940
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5-11

Déclaration de conflit d'intérêts

None

Références

Eur Respir J. 2015 May;45(5):1374-81
pubmed: 25614172
Lung Cancer. 2018 Jul;121:48-53
pubmed: 29858026
N Engl J Med. 2011 Sep 22;365(12):1079-87
pubmed: 21992121
Am J Respir Crit Care Med. 2017 Mar 15;195(6):836-837
pubmed: 28294659
PLoS One. 2018 Feb 8;13(2):e0191938
pubmed: 29420550
Ann Am Thorac Soc. 2017 Oct;14(10):1533-1538
pubmed: 28513215
Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9
pubmed: 21474646
Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81
pubmed: 17901413
Am J Respir Crit Care Med. 2017 Mar 15;195(6):835-836
pubmed: 28294650
Chest. 2018 Feb;153(2):349-360
pubmed: 28964798
Thorax. 2005 Apr;60(4):270-3
pubmed: 15790978
Am J Respir Crit Care Med. 2001 Jul 1;164(1):103-8
pubmed: 11435247
Eur Respir J. 2017 Jul 5;50(1):
pubmed: 28679612
Chest. 2014 Apr;145(4):723-728
pubmed: 24114524
Lung India. 2017 Jan-Feb;34(1):13-18
pubmed: 28144054
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
Am J Respir Crit Care Med. 2017 Mar 15;195(6):801-813
pubmed: 27684041
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049168
Ann Intern Med. 2012 May 15;156(10):684-91
pubmed: 22586007
Respir Med. 2019 Jan;146:106-112
pubmed: 30665507
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
N Engl J Med. 2012 May 24;366(21):1968-77
pubmed: 22607134
Eur Respir J. 2010 Apr;35(4):830-6
pubmed: 19840957
Radiology. 2014 Nov;273(2):570-9
pubmed: 24927326

Auteurs

Sheetu Singh (S)

Department of Chest and Tuberculosis, SMS Medical College, Jaipur, Rajasthan, India.

Mohan Bairwa (M)

Department of Community Medicine, All India Institute of Medical Sciences, New Delhi, India.

Bridget F Collins (BF)

Department of Medicine, Center for Interstitial Lung Diseases, University of Washington, Seattle, WA, USA.

Bharat Bhushan Sharma (BB)

Department of Medicine, SMS Medical College, Jaipur, Rajasthan, India.

Jyotsana M Joshi (JM)

Department of Pulmonary Medicine, Topiwala National Medical College and BYL Nair Hospital, Mumbai, Maharashtra, India.

Deepak Talwar (D)

Department of Pulmonary and Sleep Care Medicine, Metro Multispeciality Hospital, Noida, Uttar Pradesh, India.

Nishtha Singh (N)

Department of Pulmonary Medicine, Asthma Bhawan, Jaipur, Rajasthan, India.

Khushboo Pilania (K)

Jankharia Imaging Center, Mumbai, Maharashtra, India.

Parthasarathi Bhattacharya (P)

Department of Respiratory Medicine, Institute of Pulmocare and Research, Kolkata, West Bengal, India.

Neeraj Gupta (N)

Department of Respiratory Medicine, JLN Medical College and Hospital, Ajmer, Rajasthan, India.

Ravindran Chetambath (R)

Department of Pulmonary Medicine, Government Medical College, Kozhikode, Kerala, India.

Aloke G Ghoshal (AG)

Department of Respiratory Medicine, National Allergy Asthma Bronchitis Institute, Kolkata, West Bengal, India.

Surya Kant (S)

Department of Pulmonary Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.

Parvaiz A Koul (PA)

Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.

Raja Dhar (R)

Department of Pulmonology and Critical Care, Fortis Hospital, Kolkata, West Bengal, India.

Rajesh Swarnakar (R)

Department of Respiratory, Critical Care, Sleep Medicine and Interventional Pulmonology, Getwell Hospital and Research Institute, Nagpur, Maharashtra, India.

Virendra Singh (V)

Department of Pulmonary Medicine, Asthma Bhawan, Jaipur, Rajasthan, India.

Ganesh Raghu (G)

Department of Medicine, Center for Interstitial Lung Diseases, University of Washington, Seattle, WA, USA.

Classifications MeSH